Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed.

Florie BottetBenoît PeyronnetRomain BoissierBénédicte ReissJean G PrevinaireAndrea ManuntaJacques KerdraonAlain RuffionLoïc LenormandBrigitte Perrouin VerbeSarah GailletXavier GaméGilles Karsentynull null

Published in: Neurourology and urodynamics (2017)

Most patients refractory to Botox® (56.14%) draw benefits from the switch to Dysport®.

Keyphrases

escherichia coli
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
spinal cord injury
prognostic factors
botulinum toxin
patient reported outcomes
combination therapy
platelet rich plasma
replacement therapy